Bevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer

Patients with recurrent glioblastoma multiforme face a difficult path. A new analysis looked at data from 1,689 people to see if adding bevacizumab to their treatment plan helped. The study compared this drug against older methods or using standard therapy alone. Results showed that patients receiving bevacizumab had better progression-free survival and overall survival. This means the cancer took longer to grow and spread, and patients lived longer. The review also looked at surgery outcomes. Those who received bevacizumab had higher rates of successful full resection and biopsy results. This suggests the drug might make tumors easier to remove or sample. Safety was a major concern for doctors. The data showed a lower rate of central nervous system hemorrhage with standard therapy. However, bevacizumab monotherapy was associated with more favorable outcomes regarding corticosteroid use. This is a complex area where more research is needed to confirm these findings and optimize how bevacizumab is used in clinical practice.